INTELLIA THERAPEUTICS

Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions

01 Oct 2024 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting

12 Sep 2024 06:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

11 Sep 2024 09:45:32 By NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

10 Sep 2024 09:37:45 By NetDania Notify

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 Sep 2024 15:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress

08 Aug 2024 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates

01 Aug 2024 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency

30 Jul 2024 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

24 Jul 2024 15:01:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces CFO Transition

26 Jun 2024 06:30:00 By Nasdaq GlobeNewswire

Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform

25 Jun 2024 14:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024

17 Jun 2024 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Names Brian Goff to its Board of Directors

14 Jun 2024 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

02 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

09 May 2024 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates

02 May 2024 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024

29 Apr 2024 06:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

26 Apr 2024 08:47:12 By NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

25 Apr 2024 08:45:07 By NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

19 Apr 2024 08:45:17 By NetDania Notify